ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HCM Hutchmed (china) Limited

297.50
-6.50 (-2.14%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.50 -2.14% 297.50 296.00 299.00 309.00 298.00 306.00 123,751 16:35:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 304p. Over the last year, Hutchmed (china) shares have traded in a share price range of 173.60p to 338.00p.

Hutchmed (china) currently has 871,256,270 shares in issue.

Hutchmed (china) Share Discussion Threads

Showing 3926 to 3946 of 4100 messages
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
03/6/2023
09:21
yes I think you are right - geo-politics and anti-chinese sentiment are playing a major role here but what surprises me is that the NASDAQ listing seems to control London and HK prices. I was expecting and hoping that inclusion in certain chinese indexes and the southbound stock connect program would mean a big influx of chinese investors and that would mean theat the HK listing would become dominant, but that hasn't happened.
nerdofsteel
02/6/2023
21:46
The story and the performance havve not changed. Only the political background holds HCM back. I think the relationship with Takeda will go a long way to fix that.
dbadvn
31/5/2023
07:38
I may do that, although I did it at 300p and that clearly didn't work - another failed investment strategy
nerdofsteel
30/5/2023
20:21
Time to double down and load up.
its the oxman
30/5/2023
17:48
8 years of progress wiped out, now back below NASDAQ IPO levels of 2016 and below share price levels of mid 2015

The valuation is truly shocking and makes no sense at all any more

nerdofsteel
26/5/2023
01:48
Should see a turn today: Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Great to see the Takeda effect and hope more is to come. HCM also sent another news release at the same time: HUTCHMED Highlights Presentations at
the 2023 ASCO Annual Meeting

lauders
24/5/2023
17:00
shorts, malaise, geo-politics, anti-china rhetoric, Taiwan etc etc.....
nerdofsteel
20/5/2023
16:26
hmmmm not sure steeple but I'm probably
nerdofsteel
19/5/2023
19:51
https://youtu.be/8LMB6K4rTGU
steeplejack
18/5/2023
19:22
Biden Executive order to put restrictions on U.S. companies investing in chinese companies and having operations in China in sectors such as advanced semi-conductors, AI, electronics etc. Whilst the drug/biopharma sector is not mentioned specifically this Order seems to be another nail in the coffin for US listed Chinese companies. Given the fact the NASDAQ price seems to dictate the HK and London prices I think Hutchmed needs to think whether a US listing is in the best interest of shareholders.

This has been an absolute disaster for all those institutional shareholders, many of who took shares at $30.

The company needs to ditch NASDAQ and London, get a Star market listing and maintain the HK one.

The geo-politics mean this has become uninvestable. Massive financial, commercial and clinical progress has made no difference to the Company's valuation

nerdofsteel
18/5/2023
18:46
And Nasdaq price down 6.55% so far today.
mcmather
10/5/2023
18:41
sheer malaise, no interest, low volume, and clearly there will be no decent uplift here for years.....too many people have lost far too much money, and that includes all the institutional investors, some of whom paid $30+ per share.....ouch
nerdofsteel
09/5/2023
11:17
God I hope this gets bought soon
nerdofsteel
08/5/2023
17:25
Hopefully we will get bought at some point soon, the stress of continuing to lose money and holding a company whose value is governed by geo-political risk and activity in the Strait of Taiwan is far too stressful
nerdofsteel
02/5/2023
08:28
No sense at all other than China is at loggerheads with the US and its allies.The geopolitical risk is outweighing Hutchmed’s medical advances.Plus,the management of the company are pretty naive when it comes to dealing with market sentiment and nurturing investors.It is disappointing that the Takeda deal hasn’t altered perception.
steeplejack
29/4/2023
14:12
Despite the huge pipeline, clear runway to free cashflow in 2025/6 and massive progress (+ a few setbacks) this is valued the same it it was 8 years ago, which makes no sense at all.
nerdofsteel
25/4/2023
11:43
> HUTCHMED (China) Ltd


250.00 GBX −20.00 (7.41%)

maywillow
25/4/2023
11:14
Apparently Morgan Stanley reinstated HCM China "Equal-Weight" today and yet we are down nearly 7.5% on the day so far. HCM are really being a disappointment re: the share price.
lauders
18/4/2023
07:24
Aye, might well zap up after this news

Next Resistance seems to be 284p then a huge gap to 335p

Expecting an exciting day


cheers

florenceorbis
13/4/2023
12:24
PENCILLED IN RESISTANCE AT 296.50p
florenceorbis
13/4/2023
09:53
Having held HCM in varying quantities for a number of years,i can say that i haven't got the faintest idea of how the shares are likely to move from month to month let alone day to day.Its a mystery.
steeplejack
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock